文献速递细菌感染、耐药与抗菌药物医院感染防控

宿主免疫生物标志物预测实体器官移植受者革兰阴性菌血症的感染性休克与死亡

Host Immune Biosignatures Predict Septic Shock and Mortality in Solid Organ Transplant Recipients With Gram-Negative Bacteremia.
PubMed 文献 · J Infect Dis · 2026-10-05

联合模型预测不良结局(感染性休克或死亡)的AUC为0.84,显著优于临床模型的0.70(P < .001)。

要点

  • 临床-免疫联合模型AUC 0.84,优于单纯临床模型AUC 0.70(P < .001)。
  • 主成分1(广泛免疫失调)与不良结局风险升高相关(OR 1.43,95% CI 1.24-1.69)。
  • 主成分2(协调适应性免疫)与良好结局相关(OR 0.61,95% CI .43-.84)。

核心结论

  • 在实体器官移植受者革兰阴性菌血症中,免疫生物标志物可显著提升临床因素之外的不良结局预测能力。

研究设计与样本

  • 构建两个逻辑回归模型:临床模型包含年龄、移植器官和移植时间;临床-免疫模型额外纳入前两个主成分。
  • 采用AUC评估模型性能,通过重复10折交叉验证进行内部验证,并用配对t检验比较AUC。

主要发现

  • 169例实体器官移植受者中,45例(26.6%)发生不良结局(感染性休克或死亡)。
  • 临床-免疫模型较单纯临床模型具有更优的区分度(AUC 0.70 vs 0.84;P < .001)。
  • 主成分1以广泛免疫失调为特征,与不良结局风险增加相关(OR 1.43;95% CI 1.24-1.69),主要贡献来自先天促炎介质(TNF-α、IL-1β、IL-6、IL-8、MCP-1、MIP-1β、IL12p70、MIP-1α、GMCSF)、抗炎介质(IL-10、IL-4、IL-13)及IL-2。
  • 主成分2与良好结局相关(OR 0.61;95% CI .43-.84),反映协调的适应性免疫,主要贡献来自Th1、Th17和体液通路(TNFβ、IFNg、IP-10、IL-17A、IgG、IgM)。

临床怎么用

  • 对于实体器官移植后革兰阴性菌血症患者,可在临床因素基础上结合免疫生物标志物(如细胞因子谱)以更准确识别高危患者。
  • 免疫失调模式(主成分1)提示不良结局风险增高,而协调适应性免疫模式(主成分2)提示预后较好,可辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to determine whether the addition of immunologic biosignatures to a predictive model based solely on clinical data could improve the model's ability to predict patient outcome among solid organ transplant (SOT) recipients with gram-negative bacteremia (GNB). METHODS: Plasma was prospectively collected from SOT recipients with GNB. Twenty-seven cytokines, chemokines, and immunoglobulin levels were quantified. Two logistic regression models were specified: a clinical model including age, transplanted organ, and time since transplant and a clinical-immunologic model that additionally incorporated the first two principal components. Model performance was evaluated using area under the curve (AUC). Internal validation was performed by repeated 10-fold cross-validation. AUCs were compared with a paired t test. RESULTS: Of 169 SOT recipients with GNB, 45 (26.6%) experienced an adverse outcome (septic shock or death). When compared with the clinical model alone, the clinical-immunologic model demonstrated superior discrimination (AUC, 0.70 vs 0.84; P < .001). Principal component 1, characterized by broad immune dysregulation, was associated with increased risk for adverse outcome (odds ratio, 1.43; 95% CI, 1.24-1.69) and was characterized by strong contributions from innate proinflammatory mediators (TNF-α, IL-1β, IL-6, IL-8, MCP-1, MIP-1β, IL12p70, MIP-1α, and GMCSF), anti-inflammatory mediators (IL-10, IL-4, and IL-13), and IL-2. In contrast, principal component 2 was associated with a favorable outcome (odds ratio, 0.61; 95% CI, .43-.84) and reflected coordinated adaptive immunity, with dominant contributions from Th1, Th17, and humoral pathways (TNFβ, IFNg, IP-10, IL-17A, IgG, IgM). CONCLUSIONS: Immune biosignatures significantly improved prediction of adverse outcomes beyond clinical factors in SOT recipients with GNB.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Eichenberger EM, Ruffin F, Karadkhele GM, et al. Host Immune Biosignatures Predict Septic Shock and Mortality in Solid Organ Transplant Recipients With Gram-Negative Bacteremia. J Infect Dis. 2026. PMID: 42831489. doi:10.1093/infdis/jiag466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。